Article (Author postprint) (1 MB) - Limited access to UNIGE
Extrahepatic morbidity and mortality of chronic hepatitis C.
|Published in||Gastroenterology. 2015, vol. 149, no. 6, p. 1345-60|
|Abstract||Chronic hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations. Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from cutaneous and visceral vasculitis to glomerulonephritis and B-cell non-Hodgkin lymphoma. HCV-infected patients have increased rates of insulin resistance, diabetes, and atherosclerosis, which may lead to increased cardiovascular morbidity and mortality. Neurological manifestations of HCV infection include fatigue and cognitive impairment. The mechanisms causing the extrahepatic effects of HCV infection are likely multifactorial and may include endocrine effects, HCV replication in extrahepatic cells, or a heightened immune reaction with systemic effects. Successful eradication of HCV with interferon alfa and ribavirin was shown to improve some of these extrahepatic effects; sustained virological response is associated with resolution of complications of cryoglobulinemia, reduced levels of insulin resistance, reduced incidence of diabetes and stroke, and improved fatigue and cognitive functioning. The availability of new interferon-free, well-tolerated anti-HCV treatment regimens is broadening the spectrum of patients available for therapy, including those in whom interferon was contraindicated, and will likely result in greater improvements in the extrahepatic manifestations of HCV. If these regimens are shown to confer significant benefit in the metabolic, cardiovascular, or neuropsychiatric conditions associated with HCV infection, extrahepatic manifestations of HCV may become a major indication for treatment even in the absence of liver disease.|
|Keywords||Antiviral Agents/administration & dosage/pharmacology/therapeutic use — Cryoglobulinemia/epidemiology/virology — Glomerulonephritis/epidemiology/virology — Glucose Metabolism Disorders/epidemiology/virology — Hepacivirus/drug effects/pathogenicity — Hepatitis C, Chronic/drug therapy/epidemiology/immunology/mortality/virology — Humans — Interferon-alpha/pharmacology/therapeutic use — Lymphoma/epidemiology/virology — Morbidity — Ribavirin/pharmacology/therapeutic use — Vasculitis/epidemiology/virology|
|Research group||Etudes et traitement de l'hépatite C et B (554)|
|NEGRO, Francesco et al. Extrahepatic morbidity and mortality of chronic hepatitis C. In: Gastroenterology, 2015, vol. 149, n° 6, p. 1345-60. https://archive-ouverte.unige.ch/unige:84022|